Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy

Next Previous
Search
Trial Profile

A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Cellulite
  • Focus Registrational; Therapeutic Use
  • Sponsors Endo Pharmaceuticals

    • Most Recent Events

    • 07 Oct 2022 Trial focus has been changed to PD and AR as primary endpoints has been amended and number of treatment arm has been changed to 2
    • 07 Oct 2022 According to a Endo International media release, results through 3 years will be presented during the American Society for Dermatologic Surgery annual meeting 2022.
    • 13 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top